Middle-aged adults taking GLP-1s for obesity can save over $192K on lifetime medical costs, higher if they don’t have college degrees, new study finds

June 14, 2026 - 07:18

A new study suggests that middle-aged adults who take GLP-1 medications for obesity could save more than $192,000 in lifetime medical expenses. The savings are even higher for those without a college degree, according to the research paper from the National Bureau of Economic Research.

The study calculates the long-term financial impact of using drugs like Ozempic and Wegovy for weight management. Researchers found that the reduction in obesity-related health problems, such as heart disease, diabetes, and joint issues, leads to lower overall healthcare spending over a person's lifetime. The savings come from fewer hospital visits, less need for expensive surgeries, and reduced medication costs for chronic conditions.

The lead author of the paper said the goal is to put a clear dollar value on the benefits of these drugs. By showing the potential cost savings, the researchers hope to push for better access to GLP-1 treatments. Many insurance plans and government programs currently limit coverage for weight loss drugs due to their high upfront price.

The study also highlights a surprising gap. People without college degrees stand to save even more money. This may be because they face higher rates of obesity and related health issues, so the drugs have a bigger impact on their health and costs. The findings add to a growing debate about whether the long-term savings justify the short-term expense of these medications.